CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vaxess Technologies, Inc., an innovative biotechnology company developing the MIMIX™ smart release patch, was awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS), as part of BARDA’s efforts to evaluate alternative vaccination technologies. .
Vaxess will receive funding to integrate vaccine material into their MIMIX™ patch formulation and demonstrate the feasibility of this vaccination method.
The MIMIX™ platform patch technology provides a solution to vaccine global distribution and delivery. The patch, which utilizes sustained release technology, is shelf-stable, enables dramatic enhancements in protection, and can be self-applied, allowing greater ease in distribution and administration, which is critical for pandemic response. The patch also is compatible with a wide range of vaccine types, as demonstrated by Vaxess’ work towards a combination seasonal protection patch that includes both a COVID-19 vaccine and a broadly protective seasonal flu vaccine.
“By supporting development activities in parallel, BARDA has helped advance first generation COVID vaccines through clinical development remarkably fast with a focus on safety and effectiveness,” said Vaxess CEO Michael Schrader. “We’re thrilled to see them expanding their focus to include innovative platforms like MIMIX that can enable even better responses to future pandemics.”
About the MIMIX Smart Release Patch Platform
Medicine delivery, redefined. The MIMIX patch delivers medicines and vaccines through a number of tiny, painless projections that dissolve at a precisely engineered rate, releasing their treatment at its most effective dose for the most beneficial length of time. Vaxess has validated performance and compatibility with a range of molecules including proteins, killed viruses, mRNA, hormones, and live viruses.
More effective medications start with MIMIX. The MIMIX platform dramatically improves efficacy of products across a broad range of therapeutic areas by “mimicking” the prolonged exposure period that occurs during a natural infection. This prolonged exposure triggers a stronger and more enduring immune response.
Seamlessly painless. The MIMIX patch is virtually painless and after wearing it for few minutes, it is removed from the skin while the medication continues to be delivered.
About Vaxess Technologies
Vaxess Technologies is a biotechnology company headquartered in Cambridge, Massachusetts. The company is developing its proprietary sustained release smart delivery technologies to meet the need for more efficacious and easy to administer medical products. For more information please visit the company website at www.vaxess.com or send any additional inquiry to firstname.lastname@example.org.